Completed × NIH × Squamous Cell Carcinoma of Head and Neck × Clear all Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
Phase 2 Completed
55 enrolled 10 charts
Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin
Phase 2/3 Completed
196 enrolled 31 charts
Onalespib in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin
Phase 1 Completed
2 enrolled
Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer
Phase 1 Completed
19 enrolled
Cisplatin, Intensity-Modulated Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma
Phase 1 Completed
37 enrolled
Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Phase 2 Completed
14 enrolled 6 charts
Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery
Phase 2 Completed
81 enrolled 14 charts
Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Phase 1/2 Completed
58 enrolled
Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma
Phase 1/2 Completed
37 enrolled 6 charts
A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer
Phase 2 Completed
48 enrolled 14 charts
Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer
Phase 1 Completed
20 enrolled
MAESTRO HN
Phase 2 Completed
86 enrolled 11 charts
SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Phase 2 Completed
21 enrolled 10 charts
Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery
Phase 2 Completed
55 enrolled 8 charts
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
Phase 1 Completed
43 enrolled
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase 2 Completed
42 enrolled 8 charts
Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer
Phase 2 Completed
6 enrolled
Immunotoxin Therapy in Treating Patients With Advanced Cancer
Phase 1 Completed
Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer
Phase 1 Completed
Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase 2 Completed
30 enrolled
Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Phase 2 Completed
15 enrolled 8 charts
Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
Phase 2 Completed
22 enrolled 9 charts
Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer
Phase 1/2 Completed
66 enrolled
Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer
Phase 1 Completed
30 enrolled
Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Phase 2 Completed
71 enrolled 8 charts
Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer
Phase 2 Completed
11 enrolled 7 charts
Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Phase 2 Completed
9 enrolled 8 charts
Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
Phase 2 Completed
88 enrolled
Surgery and Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer That Can Be Removed During Surgery
Phase 3 Completed
200 enrolled
Endoscopic Surgery or Radiation Therapy in Treating Patients With Stage 0, Stage I, or Stage II Laryngeal Cancer of the Glottis
Phase 2 Completed
50 enrolled
Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer
Phase 1/2 Completed
45 enrolled
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
Phase 1 Completed
41 enrolled
Erlotinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Mouth or Throat Cancer
Phase 1 Completed
48 enrolled
Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Head and Neck Cancer
Phase 3 Completed
Amifostine to Treat Side Effects of Treatment in Patients Receiving Radiation Therapy and Cisplatin for Advanced Head and Neck Cancer
Phase 2 Completed
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Mouth Cancer
Phase 1/2 Completed
Radiation Therapy in Treating Patients With Head and Neck Cancer
Phase 3 Completed
460 enrolled
Combination Chemotherapy in Treating Patients With Advanced Head and Neck Cancer
Phase 3 Completed
Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors
Phase 2 Completed
Flavopiridol in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Phase 2 Completed
Interleukin-2 Gene or Methotrexate in Treating Patients With Recurrent or Refractory Stage III or Stage IV Head and Neck Cancer
Phase 2 Completed
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer
Phase 1 Completed
Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors
Phase 1 Completed
30 enrolled
Docetaxel and Radiation Therapy in Treating Patients With Stage II or Stage III Cancer of the Larynx or Hypopharynx
Phase 2 Completed
50 enrolled
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Phase 1 Completed
15 enrolled
Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck
Phase 2 Completed
144 enrolled
Gefitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
Phase 2 Completed
60 enrolled
BMS-247550 Plus Cisplatin in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase 1/2 Completed
27 enrolled
Thalidomide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Phase 2 Completed
47 enrolled